Skip to main content
TipRanks
Go Ultimate75% OFF

NovoCure (NVCR) AI Stock Analysis

1,591 Followers
NVCR

NovoCure

(NASDAQ:NVCR)

Select Model
Rating:49Neutral
Price Target:$13.00â–²(15.04% Upside)
Action:reiterated
Date:11/09/26

NVCR’s score is held back primarily by weak current profitability and negative free cash flow, along with bearish technical trends. Offsetting factors include very strong revenue growth, high gross margins and reduced leverage, plus a constructive earnings outlook with raised guidance; however, the FDA Not Approvable letter for Optune Mya adds material regulatory risk that limits the upside implied by the call.

Positive Factors
Patient and Revenue GrowthRising active-patient counts and record quarterly revenue indicate continued adoption of NovoCure’s therapy platform across existing and newer markets. This supports recurring therapy-related revenue and provides a durable base for further growth as commercial execution expands.
Negative Factors
Unproven Sustainable ProfitabilityNovoCure has not yet demonstrated durable self-funded economics despite strong revenue and gross-margin performance. Continued net losses and negative free cash flow could constrain investment capacity over time and leave profitability dependent on further growth and operating improvement.

NovoCure (NVCR) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%NVCR-1.31%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.32B
Dividend Yield
―
Average Volume (3M)
1.52M
Price to Earnings (P/E)
-10.7
Beta (1Y)
1.22
Revenue Growth
12.94%
EPS Growth
33.87%
Country
US
Employees
1,605
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

NovoCure Business Overview & Revenue Model

Company Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, an...

How the Company Makes Money

NovoCure primarily makes money by selling and providing access to its TTFields therapy devices (e.g., Optune and related TTFields systems) for approved cancer indications. Revenue is generated when eligible patients use the device over time; payment...

NovoCure Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:-20.25%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Management reported record patient levels and revenue, raised 2026 revenue and adjusted EBITDA guidance, delivered substantial year-over-year improvement in profitability metrics, and highlighted momentum in Optune Gio and Optune Lua in Japan. The principal negative issue was the U.S. OptunePax launch slowdown caused by practice disruption and limited access following the introduction of diraxonrasib, alongside a foreign exchange headwind and expected quarter-to-quarter EBITDA variability.

Positive Updates

Record GBM Patient Growth
Optune Gio reached 4.73 thousand GBM patients on therapy, an 11% increase year over year and the highest GBM active patient count to date. Growth included contributions from both new and established markets, with further adoption opportunities identified across active markets.

Negative Updates

OptunePax U.S. Launch Momentum Slowed
Novocure ended the quarter with 276 active OptunePax patients and $3.7 million in net revenue, but management acknowledged significant challenges and a slowdown in U.S. momentum during the quarter following the introduction of diraxonrasib.

Company Guidance

Novocure raised 2026 net revenue guidance to between $736 million and $743 million, representing 12% to 13% growth, including net revenues from Optune Lua and OptunePax collectively between $30 million and $34 million; it expects to maintain gross margin in the mid to high 70s through the final quarter of 2026 and updated full-year adjusted EBITDA guidance to a range of $24 million to $34 million. The company expects to keep R&D costs roughly at or below current levels for the foreseeable future, with 2027 R&D expenses flat to slightly declining, and remains committed to adjusted EBITDA breakeven on a full year basis, with cash flow breakeven as the next goal. It remains committed to delivering double digit top line growth into the future, expects OptunePax to return to growth in the coming quarters, expects a final decision on the Optune Maya PMA application by year end with a potential launch in early 2027, and expects reimbursement for OptunePax in Japan in the first half of 2027, also described as early in 2027 first quarter of 27.

NovoCure Financial Statement Overview

Summary

Financials are improving but still transitional. Revenue growth is very strong and gross margin is robust (~76%), and the balance sheet risk has improved with debt reduced sharply. However, operating and net income remain negative (TTM net margin ~-21%) and free cash flow is still negative (~-$20M), indicating the business is not yet consistently profitable or self-funding.

Income Statement

44Neutral

Balance Sheet

63Positive

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue725.39M655.35M605.22M509.34M537.84M535.03M
Gross Profit558.67M488.47M468.04M381.06M422.97M420.15M
EBITDA-104.21M-121.60M-109.58M-177.45M-67.89M-38.38M
Net Income-121.73M-136.23M-168.63M-207.04M-92.53M-58.35M
Balance Sheet
Total Assets828.71M804.33M1.24B1.15B1.19B1.14B
Cash, Cash Equivalents and Short-Term Investments463.48M457.52M959.87M910.62M969.42M938.51M
Total Debt231.55M290.00M683.35M596.24M584.27M581.90M
Total Liabilities478.10M463.86M880.61M783.63M750.48M729.00M
Stockholders Equity350.61M340.47M360.18M362.50M441.17M410.49M
Cash Flow
Free Cash Flow-20.30M-75.68M-69.22M-100.43M9.43M58.59M
Operating Cash Flow3.59M-49.03M-26.37M-73.34M30.79M82.76M
Investing Cash Flow314.46M437.28M-140.24M184.15M-139.96M-144.83M
Financing Cash Flow-551.47M-451.34M90.31M15.79M15.49M25.70M

NovoCure Technical Analysis

Technical Analysis SentimentNegative
Last Price11.30

Price Trends

50DMA14.70Negative
100DMA15.75Negative
200DMA14.79Negative

Market Momentum

MACD-0.91Positive
RSI30.71Neutral
STOCH5.96Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVCR, the sentiment is Negative. The current price of 11.30 is below the 20-day moving average (MA) of 13.49, below the 50-day MA of 14.70, and below the 200-day MA of 14.79, indicating a bearish trend. The MACD of -0.91 indicates Positive momentum. The RSI at 30.71 is Neutral, neither overbought nor oversold. The STOCH value of 5.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NVCR.

NovoCure Risk Analysis

NovoCure disclosed 40 risk factors in its most recent earnings report. NovoCure reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

NovoCure Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

NVCR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DCTHDCTH72Outperform$691.24M111.245.56%―38.13%709.17%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NVCRNVCR49Neutral$1.32B-10.68-35.81%―12.94%33.87%
SRTSSRTS45Neutral$38.52M-2.41-38.65%―-53.33%-429.93%
CATXCATX43Neutral$111.56M-0.62-41.91%―-79.53%14.45%
ARAYARAY41Neutral$7.65M-0.45-36.60%―-12.50%5.33%
TLSITLSI37Underperform$140.06M-4.62759.69%―15.38%75.82%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%NVCRARAYDCTHCATXSRTSTLSIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NVCR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NVCRNovoCure Ltd.11.30-0.15-1.31%
ARAYAccuray Incorporated2.55-36.32-93.44%
DCTHDelcath Systems, Inc.19.8711.22129.71%
CATXPerspective Therapeutics, Inc.0.92-1.36-59.52%
SRTSSensus Healthcare, Inc.2.34-1.70-42.08%
TLSITrisalus Life Sciences, Inc.2.27-2.33-50.65%

NovoCure Corporate Events

Product-Related AnnouncementsRegulatory Filings and Compliance

NovoCure Receives FDA Not Approvable Letter for Optune Mya

Negative
Nov 9, 2026

On November 9, 2026, Novocure received a Not Approvable Letter from the U.S. Food and Drug Administration for its application seeking approval of Optune Mya for adults with brain metastases from non-small cell lung cancer following stereotactic radia...

Business Operations and StrategyProduct-Related Announcements

NovoCure Gains Japanese Approval for Optune Pax Pancreatic Therapy

Positive
Oct 1, 2026

On October 1, 2026, Novocure reported that Japan’s Ministry of Health, Labour and Welfare approved its Optune Pax device for adult patients with unresectable locally advanced pancreatic cancer, used alongside gemcitabine and nab-paclitaxel. The appro...

Executive/Board Changes

NovoCure Announces Routine Board Transition After Director Retirement

Neutral
Sep 9, 2026

NovoCure Limited announced that director Timothy Scannell retired from its Board, with his seat formally vacated in accordance with the company’s Articles of Association effective September 2, 2026. His departure after five years of service was not t...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026